Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
5.79 USD | +8.63% | +4.55% | +1.77% |
04:37pm | UBS Adjusts Monte Rosa Therapeutics Price Target to $20 From $22, Maintains Buy Rating | MT |
Mar. 14 | Monte Rosa Therapeutics Q4 Net Loss Narrows; Shares Decline | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.77% | 268M | |
+2.55% | 42.75B | |
+47.70% | 41.61B | |
+12.31% | 41.34B | |
-12.36% | 26.59B | |
+8.52% | 25.49B | |
-22.90% | 18.12B | |
+30.87% | 12.24B | |
-1.44% | 11.76B | |
+8.41% | 11B |
- Stock Market
- Equities
- GLUE Stock
- News Monte Rosa Therapeutics, Inc.
- Wells Fargo Upgrades Monte Rosa Therapeutics to Overweight From Equalweight, Price Target at $18